Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

0.00%

20.5¢ resapp health limited

RAP - The Next Phase, page-4

First 4 Last

Share
Profile

Follow
rockboy

2,547 Posts.

217

16/05/16

10:22

Post #: 17775048
Share

Originally posted by Wise_One ↑

Hi All, as a RAPper from the beginning, I thought it would be nice to provide a summary of where we are and what we have to expect over the remainder of Q2 for which we now officially enter the 2nd half of the quarter!

From a news-flow perspective, the next 6 weeks could see the following Anns:
- Partner for US trial (imminent)
- Interim Adult trial results
- Update on WHO partnership (possible)
- MOU with telehealth provider (possible)
- Global Expansion Update (possible - see below for more detail)
- FDA Submission (end of Q2)

I would also like to reinforce some excellent points from the latest investor presentation (3 May - note the relevant page numbers of the slides below) which include:
- Targeting parallel approval in Europe (CE MARK) - page 11
- "Active Partnership Discussions in ALL regions" - page 11
- "Clinical collaborations to be announced shortly" - page 13
- "Potential European, Australian and Asian market entry in parallel to US" - page 16

With all of this taken in to consideration, coupled with the passing of 4-weeks since the CR to allow for staggers to exit, it is no coincidence that we saw a rush of volume / price late last week which IMO will continue and be consistently strong until the end of Q2.

Also note that we are presenting in the "ASX Spotlight Series - Asia" in Singapore (24-May) and Hong Kong (26-May). It has been a nice pattern of late that huge milestones are ticked off prior to a fresh round of investor briefings and again, the timing of these presentations to international investors is no coincidence IMO.

I am expecting one of the above milestones to be announced this week which should see RAP hit all time highs (>32c) and then there will be no stopping the train as the remainder of the Q2 milestones are ticked off.

Longer term, $1-$2 by FDA approval is well & truly in sight which will see RAP become a >$1B Mkt Cap company before the end of the year!

A final little note is that we have been consistently trading above 150m Mkt Cap for a while now which will put us in line for ASX300 admission upon the next index rebalance. This will see mandatory buying from index related funds... adding to the RAP demand!!

Expand

thanks @Wise_One ... v nice

plenty to look forward to in q2 ... and for the rest of 2016

FA ---> remains strong
global expansion underway ... huge potential market
near term commercialisation ... towards the end of 2016
TA ---> 8 / 9 month uptrend in tact
cashed up to the tune of ~ $15m
telehealth ... right place, right time

RAP Price at posting: 25.0¢ Sentiment: Buy Disclosure: Held
22 Upvote

0 Great analysis

Reply

Top Stories

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

VMM

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries